Showing results (1-10 of 424) with videos related to
Sort By:
Pageof 43
Expert Opinion on Investigational Drugs|November 30, 2002
The alpha v integrin antagonists as novel anticancer agents: an updateJanet S Kerr, Andrew M Slee, Shaker A MousaAnticancer Research|April 9, 2005
Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonistShaker A Mousa, Seema Mohamed, Eric J Wexler, et al.Journal of Neuroscience Methods|December 14, 2001
An objective procedure for ischemic area evaluation of the stroke intraluminal thread model in the mouse and ratEric J Wexler, Elaine E Peters, Armando Gonzales, et al.Cardiovascular Drug Reviews|October 25, 2002
The low molecular weight heparin, tinzaparin, in thrombosis and beyondShaker A MousaMedicinal Research Reviews|December 25, 2002
alphav Vitronectin receptors in vascular-mediated disordersShaker A MousaCurrent Opinion in Investigational Drugs (London, England : 2000)|September 5, 2002
Heparin and low molecular weight heparin in thrombosis and beyondShaker A MousaJournal of Cellular Biochemistry|February 22, 2005
Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationshipShaker A MousaDrugs of Today (Barcelona, Spain : 1998)|June 28, 2006
Role of current and emerging antithrombotics in thrombosis and cancerShaker A MousaMethods in Molecular Biology (Clifton, N.J.)|July 10, 2010
In vivo models for the evaluation of antithrombotics and thrombolyticsShaker A MousaTimely Topics in Medicine. Cardiovascular Diseases|October 27, 2006
Role of current and emerging antithrombotics in thrombosis and cancerShaker A MousaPageof 43